VIPER NextGen Solution from Intrado Revolutionizes Emergency Response Communications
'VIPER NextGen was designed with the future in mind,' said Jeremy DeMar, Senior Manager, Government and Regulatory Affairs at Intrado. 'The flexible platform is incredibly robust with georedundant failover, critical cybersecurity protocols, and local survivability built in. We designed a solution that's easy to deploy, learn, and upgrade with future enhancements, enabling even small PSAPs with limited resources to get up and running quickly. And while it works with AT&T and other i3 ESInets, we wanted to bring this new technology to legacy networks as well. VIPER NextGen also supports CAMA and RFAI, enabling cloud call handling adoption in areas previously unable to do so.'
VIPER NextGen offers an easy to use, map centric interface which simplifies workflows and reduces response time. In addition, VIPER NextGen facilitates rapid onboarding of new 9-1-1 call takers, delivering an average 90% reduction in onboarding time. Innovative AI-driven tools are baked right into the VIPER NextGen solution. PSAPs can now take advantage of automated two-way voice and text translation in over 40 languages, enabling emergency callers to easily converse with 9-1-1 telecommunicators. Voice-to-text transcription provides live call transcripts, delivering faster, more efficient communications both inside and outside the PSAP.
Additional key features and benefits of VIPER NextGen include:
'Emergency communications technology must continue to advance to meet evolving public safety demands, and platforms like Intrado's VIPER NextGen are driving the entire sector forward in our mission to serve and protect communities,' said Maggie Goodrich, CEO and Co-Founder of TacLogix.
For more information about VIPER NextGen, visit: intrado.com/psap-solutions/viper-nextgen.
About Intrado
Intrado is the essential partner for those committed to saving lives and protecting communities anywhere in the world. As a leading global provider of trusted emergency response solutions, Intrado improves public safety outcomes by connecting help to those in need. The company blends legacy intelligence, modern technology, and passionately dedicated people to create end-to-end solutions that are innovative, resilient, intuitive, and insightful. For more information, visit www.intrado.com.
Media Contact
[email protected]
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Scientists May Have Identified a Natural Alternative to Ozempic
Scientists may have identified a way to naturally regulate blood sugar levels and sugar cravings in a similar fashion to drugs like Ozempic. In mice and humans, the key to unlocking this natural process was found to be a gut microbe and its metabolites – the compounds it produces during digestion. By increasing the abundance of this one gut microbe in diabetic mice, researchers led by a team at Jiangnan University in China showed they can "orchestrate the secretion of glucagon-like peptide-1". Related: Glucagon-like peptide-1 (GLP-1) is a hormone that is naturally produced by the body and which helps regulate blood sugar levels and feelings of fullness. GLP-1's release is stimulated by certain foods and gut microbes, and its mechanism of action is mimicked by drugs like semaglutide (the ingredient behind Ozempic). People with type 2 diabetes typically have impaired GLP-1 function, leading to issues with blood sugar control, which is why Ozempic and other GLP-1 agonists work as treatments. These drugs mimic natural processes in the body, and while they have proved very effective, some researchers want to figure out how to get the body to produce more GLP-1 on its own. "A growing body of research has revealed that our cravings for dietary components originate from signals sent from the gut, a key organ in transmitting dietary preferences," explain the authors in their paper published in January. "However, which genes, gut flora, and metabolites in the gut microenvironment are involved in the regulation of sugar preference is currently unclear." The new research suggests gut microbes like Bacteroides vulgatus and their metabolites may help shape a person's sweet tooth. In experiments, if mice could not produce a gut protein, called Ffar4, the researchers found the gut colonies of B. vulgatus shrank. This, in turn, decreased the release of a hormone called FGF21, which is tied to sugar cravings. In studies of mice taking GLP-1 agonists, researchers have found the drugs stimulate FGF21. Meanwhile, in humans, some studies suggest that those with genetic variants for the FGF21 hormone are about 20 percent more likely to be top-ranking consumers of sweet foods. In a blood analysis of 60 participants with type 2 diabetes and 24 healthy controls, the researchers in China found that Ffar4 mutations, which reduce FGF21 production, are linked to an increased preference for sugar, "which may be an important contributor to the development of diabetes." What's more, the gut microbiome could be a key mediator of that process. Sure enough, the research team found that when mice were treated with a metabolite of B. vulgatus, it boosted GLP-1 secretion, which then also triggered the secretion of FGF21. Together, this meant more blood sugar control and fewer sugar cravings in mice. Whether the same will extend to humans remains to be seen, but the authors claim their study "provides a strategy for diabetes prevention." The study was published in Nature Microbiology. An earlier version of this article was first published in January 2025. Related News New Research Confirms Weight-Loss Drug Link With Sudden Vision Loss This Amazing Blob Is Stunningly Similar to The Human Brain Air Conditioning Could Put You at Risk of 'Sick Building Syndrome' Solve the daily Crossword
Yahoo
an hour ago
- Yahoo
Erectile Dysfunction Devices Market Set to Surge at a CAGR of ~8% by 2032 with Rising Global Demand and Technological Advancements
The demand for erectile dysfunction devices is largely fueled by the growing incidence of ED, especially among men with chronic health conditions like cardiovascular disease, diabetes, and hypertension. While ED can affect men across all age groups, it is more commonly seen in older adults who often have associated health concerns such as prostate cancer, anxiety, and depression. Furthermore, the expanding elderly male population, combined with higher rates of obesity and sedentary behaviors like smoking and physical inactivity, are significant contributor to the market's expansion. New York, USA, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Erectile Dysfunction Devices Market Set to Surge at a CAGR of ~8% by 2032 with Rising Global Demand and Technological Advancements | DelveInsight The demand for erectile dysfunction devices is largely fueled by the growing incidence of ED, especially among men with chronic health conditions like cardiovascular disease, diabetes, and hypertension. While ED can affect men across all age groups, it is more commonly seen in older adults who often have associated health concerns such as prostate cancer, anxiety, and depression. Furthermore, the expanding elderly male population, combined with higher rates of obesity and sedentary behaviors like smoking and physical inactivity, are significant contributor to the market's expansion. DelveInsight's Erectile Dysfunction Devices Market Insights report provides the current and forecast market analysis, individual leading erectile dysfunction devices companies' market shares, challenges, erectile dysfunction devices market drivers, barriers, trends, and key erectile dysfunction devices companies such as Coloplast Group, Zimmer Aesthetics, Augusta Medical Systems, Medispec, MTS Medical, Boston Scientific Corporation, NOVAmedtek, Promedon GmbH, and others in the market. Erectile Dysfunction Devices Overview Erectile dysfunction devices play a crucial role in the management of erectile dysfunction, a condition characterized by the inability to achieve or maintain an erection sufficient for satisfactory sexual performance. These devices are particularly valuable for men who cannot take or do not respond to oral pharmacological treatments. Common types of ED devices include vacuum erection devices (VEDs), penile implants (inflatable or malleable), and constriction rings. VEDs work by creating a vacuum around the penis to draw blood into it, while penile implants offer a more permanent solution through surgically inserted devices that mimic the natural erection process. These options provide men with greater control over their sexual function and can significantly improve the quality of life and Dysfunction Devices Regional Market Insights North America dominated the erectile dysfunction devices market in 2024, owing to several critical factors. This leadership is primarily driven by the increasing incidence of erectile dysfunction and rising awareness about the condition among the regional population. Contributing to this trend is the growing number of individuals affected by prostate cancer, hypertension, and diabetes—key risk factors for erectile dysfunction. Additionally, major industry players in the region are prioritizing technological progress and product development. For instance, in January 2025, Comphya SA, an innovative medtech company, received Investigational Device Exemption (IDE) approval from the U.S. Food and Drug Administration (FDA) to commence clinical trials for CaverSTIM, the first implantable neuromodulator designed to treat erectile dysfunction. These advancements are expected to drive significant growth in the market by providing new treatment options for affected individuals. As a result, the convergence of rising erectile dysfunction cases, a high burden of contributing health conditions, and ongoing innovation in device technology is projected to fuel substantial market growth in North America between 2025 and 2032. To know more about why North America is leading the market growth in the erectile dysfunction devices market, get a snapshot of the Erectile Dysfunction Devices Market Outlook Recent Developments in the Erectile Dysfunction Devices Market In January 2025, Comphya SA, a pioneering medical technology company, announced that the FDA granted Investigational Device Exemption (IDE) approval to initiate clinical trials for CaverSTIM, the first implantable neuromodulator developed to treat erectile dysfunction. In June 2024, Ohh-Med Medical Ltd. launched VerticaPlus with a cloud-based mobile app. Vertica is a pioneering medical device designed to enhance erection quality over time by targeting the Tunica Albuginea in the penis, thereby reducing leakage and outflow. This innovative approach optimizes the natural erectile mechanism without relying on medication, allowing for complete spontaneity in intimate relations and eliminating associated side effects. To read more about the latest highlights related to the erectile dysfunction devices market, get a snapshot of the key highlights entailed in the Erectile Dysfunction Devices Key Players in the Erectile Dysfunction Devices Market The erectile dysfunction devices market is driven by several key players that focus on technological innovation, product development, and strategic partnerships to expand their market share. Prominent companies such as Coloplast Group, Zimmer Aesthetics, Augusta Medical Systems, Medispec, MTS Medical, Boston Scientific Corporation, NOVAmedtek, Promedon GmbH, Global Life Technologies LLC, Zephyr Surgical Implants, Owen Mumford, Vacurect, T.E. Inc., SILIMED, STORZ MEDICAL AG, Rigicon, Inc., TIMM Medical, Alma Lasers, Comphya SA, Ohh-Med Medical Ltd., and others are at the forefront of the industry. These firms offer a range of medical devices, including vacuum erection devices (VEDs), penile implants, and constriction rings, catering to diverse patient needs. Their emphasis on clinically effective solutions, robust research and development pipelines, and global distribution networks has positioned them as leaders in the growing erectile dysfunction devices market. Which MedTech key players in the erectile dysfunction devices market are set to emerge as the trendsetter explore @ Top Erectile Dysfunction Devices Companies Erectile Dysfunction Devices Market Key Factor Analysis Erectile Dysfunction Devices Market Drivers The erectile dysfunction devices market is primarily driven by the growing prevalence of erectile dysfunction worldwide. This rise is closely linked to an increase in the number of risk factors, such as diabetes, cardiovascular diseases, obesity, and lifestyle-related conditions that contribute to the onset of erectile dysfunction. Additionally, the expanding geriatric male population, which is more susceptible to such conditions due to age-related physiological changes, is further propelling the demand for effective treatment solutions, including medical devices designed to manage erectile dysfunction. Erectile Dysfunction Devices Market Restraints and Challenges One of the major restraints in the erectile dysfunction devices market is the high cost of advanced devices, which limits accessibility for a large segment of the patient population, particularly in developing regions. Additionally, the complexity of these devices and the potential risk of malfunction pose significant challenges, often leading to patient hesitation and reduced adoption rates. These factors collectively hinder the widespread use and acceptance of erectile dysfunction devices despite their clinical benefits. Erectile Dysfunction Devices Market Opportunities The erectile dysfunction devices market presents significant growth opportunities driven by the integration of advanced technologies, such as robotic implantation and other innovative approaches. These advancements are enhancing the precision, safety, and effectiveness of erectile dysfunction treatments, leading to improved patient outcomes and satisfaction. As healthcare systems increasingly adopt minimally invasive and tech-enabled solutions, the demand for technologically sophisticated erectile dysfunction devices is expected to rise, creating a favorable environment for market expansion. Get a sneak peek at the erectile dysfunction devices market dynamics @ Global Erectile Dysfunction Devices Market Report Report Metrics Details Coverage Global Study Period 2022–2032 Erectile Dysfunction Devices Market CAGR ~8% Erectile Dysfunction Devices Market Size by 2032 USD 3 Billion Key Erectile Dysfunction Devices Companies Coloplast Group, Zimmer Aesthetics, Augusta Medical Systems, Medispec, MTS Medical, Boston Scientific Corporation, NOVAmedtek, Promedon GmbH, Global Life Technologies LLC, Zephyr Surgical Implants, Owen Mumford, Vacurect, T.E. Inc., SILIMED, STORZ MEDICAL AG, Rigicon, Inc., TIMM Medical, Alma Lasers, Comphya SA, Ohh-Med Medical Ltd., and others Erectile Dysfunction Devices Market Assessment Erectile Dysfunction Devices Market Segmentation Erectile Dysfunction Devices Market Segmentation By Product: Penile Implants, Shockwave Therapy Devices, Vacuum Therapy Devices, and Others Erectile Dysfunction Devices Market Segmentation By Approach: Invasive and Non-Invasive Erectile Dysfunction Devices Market Segmentation By End User: Hospitals & Clinics, Ambulatory Surgical Centers, and Others Erectile Dysfunction Devices Market Segmentation By Geography: North America, Europe, Asia-Pacific, and Rest of World Porter's Five Forces Analysis, Product Profiles, Case Studies, KOL's Views, Analyst's View Interested in knowing the erectile dysfunction devices market by 2032? Click to get a snapshot of the Erectile Dysfunction Devices Market Analysis Table of Contents 1 Erectile Dysfunction Devices Market Report Introduction 2 Erectile Dysfunction Devices Market Executive Summary 3 Competitive Landscape 4 Regulatory Analysis 5 Erectile Dysfunction Devices Market Key Factors Analysis 6 Erectile Dysfunction Devices Market Porter's Five Forces Analysis 7 Erectile Dysfunction Devices Market Layout 8 Erectile Dysfunction Devices Market Company and Product Profiles 9 KOL Views 10 Project Approach 11 About DelveInsight 12 Disclaimer & Contact Us Related Reports Erectile Dysfunction Market Erectile Dysfunction Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key erectile dysfunction companies, including Vigonvita Life Sciences, Futura Medical Developments, Initiator Pharma, Pharmicell Co., Ltd., BioIntegrate, Biozeus Biopharmaceutical, Can-Fite Biopharma, Fabre-Kramer Pharmaceuticals, Humanetics Pharmaceuticals, Hemostemix Inc., Ilgen Bio, Aquestive Therapeutics, MicroCures, Dicot AB, CURE Pharmaceutical, IX BIOPHARMA, Exopharm, Oncotelic Therapeutics, Blue Cell Therapeutics, S1 Biopharma, among others. Erectile Dysfunction Pipeline Erectile Dysfunction Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key erectile dysfunction companies, including Vigonvita Life Sciences, Futura Medical Developments, Initiator Pharma, Pharmicell Co., Ltd., BioIntegrate, Biozeus Biopharmaceutical, Can-Fite Biopharma, Fabre-Kramer Pharmaceuticals, Humanetics Pharmaceuticals, Hemostemix Inc., Ilgen Bio, Aquestive Therapeutics, MicroCures, Dicot AB, CURE Pharmaceutical, IX BIOPHARMA, Exopharm, Oncotelic Therapeutics, Blue Cell Therapeutics, S1 Biopharma, among others. Prostate Cancer Market Prostate Cancer Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key prostate cancer companies including AstraZeneca, Arvinas, Madison Vaccines, Phosplatin Therapeutics, Hinova Pharmaceuticals, Bristol Myers Squibb, Merck, MacroGenics, Daiichi Sankyo, Seagen, Taiho Pharmaceutical, Modra Pharmaceuticals, Xencor, Point Biopharma, Lantheus Holdings, Zenith Epigenetics, Essa Pharma, Telix Pharmaceuticals, Kintor Pharmaceutical, AB Science, Eli Lilly and Company, Exelixis among others. Prostate Cancer Pipeline Prostate Cancer Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key prostate cancer companies, including Curium, Merck, Telix Pharmaceuticals, Exelixis, AstraZeneca, AB Science, Lantheus, Pfizer, Jiangsu Hengrui Pharmaceuticals, Modra Pharmaceuticals, Bristol-Myers Squibb, MacroGenics, Syntrix Pharmaceuticals, Zenith Epigenetics, Xencor, Bristol Myers Squibb, Merus, Phosplatin Therapeutics, Laekna Therapeutics, Tavanta Therapeutics, Madison Vaccines, Taiho Pharmaceutical, Kangpu Biopharmaceuticals, Arvinas, Candel Therapeutics, Blue Earth Therapeutics, Ipsen Biopharmaceuticals, LAVA Therapeutics, Essa Pharma, Poseida Therapeutics, Janux Therapeutics, Aurigene Oncology, Sathgen Therapeutics, Full-Life Technologies, NextPoint Therapeutics, AbbVie, SL VAXiGEN, Sorrento Therapeutics, Inc., 858 Therapeutics, Avacta Life Sciences Ltd, Nammi Therapeutics, BeiGene, DualityBio, among others. Prostate Cancer Diagnostics Market Prostate Cancer Diagnostics Market Insights, Competitive Landscape, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key prostate cancer diagnostics companies, including F. Hoffmann-La Roche Ltd, Myriad Genetics, Inc., Abbott., MDx Health, Siemens Healthcare, OPKO Health, Inc., Genomic Health, Inc., Agilent Technologies, Inc., BD., BIOCEPT, INC., Proteomedix, A3P Biomedical AB, GE HealthCare., Soteria Medical BV, Bio-Techne., Indica Labs, Inc., miR Scientific, MINOMIC®, ACON Laboratories, Inc., Hologic, Inc., among others. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. CONTACT: Contact Us Shruti Thakur info@ +14699457679 in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Upturn
an hour ago
- Business Upturn
Pumpkin is Back! The Human Bean Brews Up Fall Favorites Starting August 11
By GlobeNewswire Published on August 12, 2025, 23:13 IST Medford, OR, Aug. 12, 2025 (GLOBE NEWSWIRE) — Summer's last sips are giving way to autumn's first flavors as pumpkin returns to The Human Bean menus starting August 11. This year's collection features four pumpkin-inspired beverages designed to capture the coziness of the season — from the first crisp mornings to the last golden leaves. Whether the moment calls for warm comfort or cool spice, these pumpkin-flavored specialties promise to kick off the unofficial start of fall. Pumpkin Snowy makes its seasonal return with rich espresso, creamy white chocolate and pumpkin, topped with whipped cream and a dusting of cinnamon sprinkles. Available hot, iced or as a granita. Pumpkin Java Chip stirs up fall fun with blended Java Chip, pumpkin drizzle, and a generous whipped cream topper. It's a perfect sweet treat to bring back that fall feeling! Pumpkin Granita is blended to perfection with espresso and rich pumpkin flavor, then finished with a swirl of pumpkin sauce around the cup. It's a chilly match for warm late-summer afternoons. Pumpkin Patch brings together iced matcha with a dreamy layer of Pumpkin Cold Foam — rich,creamy, and spiced just right. 'Fall represents more than a seasonal menu change—it's about nostalgia and celebrating traditions that bring people together,' said Janie Page, chief marketing officer at The Human Bean. 'Our pumpkin collection pairs with life's seasonal adventures, and there's something for everyone with this year's lineup.' Pumpkin specials and toppers, like Pumpkin Cold Foam and Cinnamon Sprinkles, are available while supplies last. More information and a drive-thru locator are available at ______ About The Human Bean With a passion for creating happy 'Human Beans', the company's drive-thrus around the U.S. have established a reputation for friendly baristas, high-quality coffee and innovative flavors. The Human Bean opened its first drive-thru espresso stand in Ashland, Oregon in 1998, and currently supports over 260 locations open or under development in 23 states. Learn more at Attachment Pumpkin is Back! The Human Bean Brews Up Fall Favorites Starting August 11 Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
